<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83447">
  <stage>Registered</stage>
  <submitdate>9/12/2008</submitdate>
  <approvaldate>3/02/2009</approvaldate>
  <actrnumber>ACTRN12609000080224</actrnumber>
  <trial_identification>
    <studytitle>Desmopressin for the Treatment of Orthostatic Hypotension and Excessive Nighttime Urination in Parkinsons Disease</studytitle>
    <scientifictitle>A Double-Blind, Placebo-controlled Crossover Clinical Trial of Desmopressin for the Treatment of Orthostatic Hypotension and Nocturia in Parkinsons Disease</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Nocturia</healthcondition>
    <healthcondition>Parkinson's Disease</healthcondition>
    <healthcondition>Orthostatic Hypotension</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Parkinson's disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Subjects will start with either nightly placebo or oral desmopressin for three weeks.  After a washout period of one week of no medication, they will then switch to the therapy they have not tried for another three weeks.  

Subjects taking desmopressin will begin with a 100 mcg nightly dose.  If this is tolerated, after one week they will increase to 200 mcg nightly, which they will take for two weeks.</interventions>
    <comparator>Oral microcellulose capsule taken nightly for three weeks</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Improvement of at least 2 points on the COMPASS-OD survey, which assesses for symptoms of low blood pressure.</outcome>
      <timepoint>Assessed at day 21 and 49</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of nocturnal bladder voids as measured by a diary</outcome>
      <timepoint>Assessed at day 21 and 49</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Improvement in sleep as measured by a survey (Epworth Sleepiness Scale)</outcome>
      <timepoint>Assessed at day 21 and 49</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Parkinson's disease
Orthostatic hypotension (blood pressure drop with standing)
A need to empty the bladder 2 or more times at night</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>History of renal failure, congestive heart failure, or cirrhosis
A history of low blood sodium
Dementia</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Subjects will be enrolled by a convenience sample through our clinic.  Treatment allocation will be done using numbered containers, with numbers assigned by a person otherwise uninvolved in the trial.</concealment>
    <sequence>Simple randomisation by using a randomization table created by a computer software.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>6/04/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>John O'Sullivan</primarysponsorname>
    <primarysponsoraddress>RBWH, Butterfield St., Herston, QLD, 4029</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Royal Brisbane &amp; Women's Hospital</fundingname>
      <fundingaddress>Butterfield St., Herston, QLD, 4029</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Melinda Burnett</sponsorname>
      <sponsoraddress>RBWH, Butterfield St., Herston, QLD, 4029</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>We plan to study 20 patients with idiopathic Parkinson's disease with complications of orthostatic hypotension and nocturia.  In an 8 week double-blinded, crossover study design, we will study the effects of oral desmopressin (or matching placebo) on orthostatic hypotension, nocturia, and sleep.</summary>
    <trialwebsite />
    <publication>Schoffer, K.L., Henderson, R. D., O'Maley, K. O'Sullivan, J. D. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord, 2007. 22(11): p. 1543-9.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Brisbane &amp; Women's Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>RBWH, Butterfield St., Herston, QLD, 4029</ethicaddress>
      <ethicapprovaldate />
      <hrec>2008/103</hrec>
      <ethicsubmitdate>1/10/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Melinda Burnett</name>
      <address>RBWH, Butterfield St., Herston, QLD, 4029</address>
      <phone>+61 7 3636 8111</phone>
      <fax />
      <email>melinda_burnett@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Melinda Burnett</name>
      <address>RBWH, Butterfield St., Herston, QLD, 4029</address>
      <phone>+61 7 3636 8111</phone>
      <fax />
      <email>melinda_burnett@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Melinda Burnett</name>
      <address>RBWH, Butterfield St., Herston, QLD, 4029</address>
      <phone>+61 7 3636 8111</phone>
      <fax />
      <email>melinda_burnett@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>